Clinicians say they're twisting in wind during FDA review of SSRIs.
Jackim
Linda Watts
LW
D000293:Adolescent; D000296:Adolescent Psychiatry / Q000592:standards*; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002665:Child Psychiatry / Q000592:standards*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013406:Suicide, Attempted / Q000523:psychology* / Q000706:statistics & numerical data; D014481:United States; D014486:United States Food and Drug Administration
D018687:Antidepressive Agents, Second-Generation; D017367:Selective Serotonin Reuptake Inhibitors